Oryzon has two drugs in clinical development, iadademstat (also known as ORY-1001), a selective LSD1 inhibitor for oncology, and vafidemstat (also known as ORY-2001), a CNS optimized LSD1 inhibitor for neurological disorders.
Oryzon has completed one Phase I clinical trial with iadademstat in patients with acute leukemia, and especially in those with alteration in the MLL gene and other specific genomic alterations. Currently, Oryzon has two Phase IIa studies ongoing with iadademstat: the ALICE study, to evaluate the safety, tolerability, dose finding and efficacy of iadademstat in combination with standard treatment with azacitidine in newly diagnosed patients with Acute Myeloid Leukemia (AML) not eligible for intensive chemotherapy, and the CLEPSIDRA study, to evaluate the safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with small cell lung cancer. Preliminary clinical results have already been reported in both clinical trials.
With vafidemstat , after completing one Phase I clinical trial in healthy volunteers, Oryzon has performed Phase IIa clinical trials in aggressiveness in patients with different psychiatric disorders, namely Autism Spectrum Disorder, Borderline Personality Disorder and adult Attention Deficit Hyperactivity Disorder (REIMAGINE study), and in aggressive/agitated patients with moderate or severe Alzheimer’s disease (REIMAGINE-AD study), with positive preliminary clinical results reported in both clinical trials. Additional Phase IIa clinical trials with vafidemstat are ongoing: the ETHERAL and ETHERAL-US studies in patients with mild to moderate Alzheimer’s disease, and the SATEEN study in relapse-remitting and secondary progressive multiple sclerosis. An additional Phase IIa trial in severely ill COVID-19 patients has recently started (ESCAPE study).
Both Oryzon’s experimental drugs target the Lysine-specific demethylase LSD1 , a critical enzyme involved in the regulation of histone and chromatin remodeling. By doing this, they regulate important genes involved in the control of cellular differentiation, survival and proliferation.
Our compounds are investigational medicines, meaning that they are being evaluated in clinical trials and are not yet available for use outside of a clinical trial setting. Approval by regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) at the end of their clinical development is the way to make our medicines available to the patients in need of these medicines.
In the meantime, our priority is to advance in the clinical trials in order to obtain the data required for the review and approval of our medicaments by the regulatory authorities. We provide below a summary of the clinical trials sponsored by Oryzon.